Drug intelligence / Profile preview

selegiline + alpha-tocopherol

Development stage
Unknown
Lead developer
Somerset Pharma
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Selegiline + alpha-tocopherol is a combination therapy consisting of two agents: - Selegiline, a selective monoamine oxidase B (MAO-B) inhibitor that increases brain catecholamine levels by inhibiting their breakdown. It is primarily used in the management of Parkinson's disease and has been investigated for its neuroprotective effects in Alzheimer's disease. - Alpha-tocopherol (vitamin E), a fat-soluble antioxidant that protects cell membranes from oxidative damage. This combination was studied for its potential to slow the progression of moderately severe Alzheimer's disease. Clinical trials demonstrated that both agents individually delayed clinical deterioration—measured as time to death, institutionalization, loss of basic activities of daily living, or severe dementia—compared to placebo. However, the combination did not provide additional benefit over either agent alone and was associated with an increased risk of falls and syncope[1][2][5]. The mechanism involves MAO-B inhibition (selegiline) leading to increased dopamine availability and antioxidant protection (alpha-tocopherol)[1][5].

Other names
selegiline and alpha-tocopherolselegiline and vitamin Edeprenyl + alpha-tocopherol
02

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)TTPA (Alpha-tocopherol transfer protein)

Beyond the preview

Go deeper on selegiline + alpha-tocopherol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on selegiline + alpha-tocopherol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call